Chapter 3: Pharmacodynamics — Module 8: Advanced Pharmacodynamic Concepts — Hysteresis, Indirect Response and Drug Interactions
1. A 74-year-old man with a hip fracture is admitted to the orthopedic ward and given morphine 10 mg IV for pain. He achieves adequate analgesia within 20 minutes. Thirty minutes after the dose, his nurse notes worsening respiratory depression despite his pain scores remaining controlled. The attending physician explains that this is an expected pharmacodynamic phenomenon. Which of the following best explains why respiratory depression is worsening at a time when analgesia is already established?
A) The worsening respiratory depression reflects pharmacokinetic accumulation -- morphine undergoes saturable hepatic metabolism, and at the 10 mg dose the metabolic pathway is overwhelmed, causing plasma morphine concentrations to continue rising for 30-45 minutes after the IV dose
B) The worsening respiratory depression reflects development of acute pulmonary edema -- morphine-induced histamine release causes increased pulmonary capillary permeability, and the progressive fluid accumulation produces worsening respiratory compromise distinct from the CNS opioid effect
C) The worsening respiratory depression reflects conversion of morphine to morphine-6-glucuronide (M6G), an active metabolite with higher intrinsic efficacy at mu-opioid receptors than morphine itself; M6G accumulates over 30-45 minutes and amplifies the respiratory depressant effect beyond what morphine alone produces
D) The worsening respiratory depression reflects tolerance reversal -- the patient was previously on chronic opioid therapy that was recently discontinued, and the 30-minute lag reflects the time required for previously upregulated opioid receptors to re-engage with exogenous morphine after a period of receptor reset
E) The worsening respiratory depression reflects the plasma-biophase distributional lag -- morphine's relatively low lipophilicity means CNS equilibration is slow; at 20 minutes, plasma morphine concentrations are falling but CNS biophase concentrations are still rising toward their peak; the analgesic effect is established but the full respiratory depressant effect, which requires the same CNS equilibration, has not yet peaked; in an elderly patient with reduced respiratory reserve, this delayed peak CNS effect produces clinically significant respiratory depression
ANSWER: E
Rationale:
This scenario directly illustrates the clinical consequence of counterclockwise hysteresis and the plasma-biophase distributional lag of morphine. After an IV morphine dose, plasma concentrations peak almost immediately and then begin to fall as the drug distributes. However, CNS biophase concentrations (at the mu-opioid receptors in the brainstem respiratory centers and elsewhere) continue to rise for 15-30 minutes after the plasma peak, as morphine slowly crosses the blood-brain barrier. In most patients, both analgesia and respiratory depression track the same CNS biophase concentration. However, the clinical presentation described -- adequate analgesia achieved at 20 minutes with worsening respiratory depression at 30 minutes -- reflects the ongoing rise in CNS drug concentration as distribution continues. In a 74-year-old patient, age-related reduction in respiratory reserve and increased CNS sensitivity to opioids (pharmacodynamic changes) mean that the still-rising biophase morphine concentration produces clinically significant respiratory depression at concentrations that are already analgesic. This is why the clinical teaching is to wait 15-20 minutes before assessing the full effect of an IV morphine dose and before administering a repeat dose.
Option A: Option A is incorrect -- IV morphine does not have saturable hepatic metabolism at clinical doses; plasma concentrations peak rapidly after IV administration and fall predictably; there is no 30-45 minute continued rise in plasma concentration.
Option B: Option B is incorrect -- morphine-induced histamine release does occur and can cause bronchospasm, but it does not produce progressive pulmonary edema; the scenario describes CNS opioid-mediated respiratory depression, not pulmonary edema.
Option C: Option C is incorrect -- while morphine-6-glucuronide (M6G) is an active metabolite with significant mu-opioid activity, its accumulation occurs over hours with repeated dosing in patients with renal impairment, not within 30-45 minutes of a single dose in an acute setting.
Option D: Option D is incorrect -- tolerance reversal requires weeks to months of abstinence and is not the explanation for a 30-minute lag in respiratory depression after a single IV dose.
2. A pharmaceutical company presents Phase II data on a novel antihypertensive drug. Drug X reduces mean arterial pressure by 18 mmHg at its maximum effect, but this maximum effect is not reached until 2 hours after dosing, despite the drug achieving peak plasma concentrations within 30 minutes. A clinical pharmacologist on the review panel raises a pharmacodynamic concern about this time course. Which of the following best describes the pharmacologist's concern?
A) The clinical pharmacologist is concerned that Drug X's 2-hour time to maximum effect reflects poor oral bioavailability -- the drug is slowly absorbed from the gastrointestinal tract, and the 2-hour lag represents the time for plasma concentrations to reach the threshold required to activate antihypertensive pathways
B) The clinical pharmacologist is concerned that Drug X's 2-hour time to maximum effect may reflect active metabolite accumulation -- a pharmacokinetically active metabolite with antihypertensive properties is being generated by hepatic metabolism over 2 hours, complicating dose-response modeling and potentially producing unpredictable drug accumulation with repeated dosing
C) The clinical pharmacologist is concerned that Drug X's 2-hour time to maximum effect reflects an indirect response mechanism -- the drug may not directly vasodilate but instead inhibit production of a vasoconstrictor or stimulate production of a vasodilator, with the full antihypertensive effect requiring the existing vasoconstrictor pool to turn over or the vasodilator pool to accumulate; this would mean the pharmacodynamic time course is governed by mediator turnover kinetics, not drug pharmacokinetics, with important implications for dosing interval, offset of action, and rebound hypertension risk
D) The clinical pharmacologist has no valid pharmacodynamic concern -- Emax is an intrinsic property of the drug-receptor interaction and a 2-hour time to Emax is within normal pharmacodynamic limits for antihypertensive agents; the peak plasma concentration at 30 minutes and maximum effect at 2 hours simply reflects normal receptor occupancy kinetics
E) The clinical pharmacologist is concerned that Drug X's 2-hour time to maximum effect indicates very slow receptor dissociation -- the drug binds irreversibly or pseudo-irreversibly to vascular smooth muscle receptors, and the 2-hour lag reflects the time required for full receptor occupancy to be achieved through slow association kinetics
ANSWER: C
Rationale:
The pharmacological concern raised here is the distinction between direct and indirect pharmacodynamic response mechanisms. A drug that directly relaxes vascular smooth muscle (e.g., by blocking calcium channels or activating potassium channels) should produce its maximum effect relatively soon after achieving peak plasma concentrations, since the drug directly mediates the biological effect. The fact that Drug X's plasma concentrations peak at 30 minutes but the antihypertensive effect continues to increase for 2 hours suggests that the drug's mechanism is indirect -- it is not directly producing vasodilation but is instead modulating an endogenous mediator system. Possibilities include inhibiting synthesis of a vasoconstrictor (analogous to warfarin and clotting factors), stimulating production or release of a vasodilator, or inhibiting degradation of an endogenous antihypertensive mediator. In each case, the full effect depends on turnover of the mediator pool, producing the characteristic time lag seen with indirect response pharmacodynamics. The clinical implications are significant: offset of action will also be prolonged (the mediator pool takes time to recover when the drug is stopped), rebound hypertension may occur if the drug is stopped abruptly and the underlying vasoconstrictor pool surges, and dosing interval must account for pharmacodynamic half-life rather than just plasma half-life.
Option A: Option A is incorrect -- poor oral bioavailability would reduce Cmax, not delay it by 90 minutes after the plasma peak; the plasma peak at 30 minutes is already achieved, so absorption is complete.
Option B: Option B is incorrect -- while active metabolite accumulation could explain a delayed effect, the scenario specifies peak plasma concentrations of the parent drug at 30 minutes; active metabolite would need to be separately measured, and this is a less parsimonious explanation than indirect pharmacodynamics.
Option D: Option D is incorrect -- a 90-minute lag between peak plasma concentration and peak pharmacodynamic effect is not within normal receptor occupancy kinetics for a directly acting drug; this temporal disconnect is pharmacodynamically significant and requires explanation.
Option E: Option E is incorrect -- slow receptor association kinetics would produce a delayed onset from the first dose but would not produce a sustained 2-hour build-up after peak plasma concentrations are achieved; pseudo-irreversible binding produces prolonged duration, not prolonged onset.
3. A 58-year-old woman with type 2 diabetes and hypertension is started on a new combination tablet containing candesartan (an angiotensin receptor blocker) and amlodipine (a calcium channel blocker). Her cardiologist mentions that this combination produces greater blood pressure reduction than either drug alone at equivalent doses -- a synergistic rather than simply additive antihypertensive effect. A medical fellow asks how two drugs with different mechanisms can produce pharmacodynamic synergism. Which of the following best explains the mechanistic basis for this synergism?
A) Candesartan blocks AT1 (angiotensin II type 1) receptors, reducing angiotensin II-mediated vasoconstriction and aldosterone release, which also activates compensatory mechanisms including baroreceptor-mediated sympathetic activation and renin release that partially limit its antihypertensive effect; amlodipine blocks L-type calcium channels in vascular smooth muscle, directly reducing vasoconstriction; amlodipine's direct vasodilation also activates the same compensatory sympathetic and renin-angiotensin mechanisms; candesartan simultaneously blocks the angiotensin II component of this compensatory response, preventing the counter-regulatory activation that would otherwise blunt amlodipine's effect -- the result is that each drug removes a counter-regulatory mechanism that limits the other's effect, producing greater-than-additive blood pressure reduction
B) Candesartan and amlodipine produce synergism because they both ultimately reduce intracellular calcium in vascular smooth muscle -- candesartan reduces IP3-mediated calcium release from the sarcoplasmic reticulum while amlodipine reduces calcium influx through L-type channels; by blocking both routes of calcium entry simultaneously, the combination depletes intracellular calcium more completely than either drug alone, producing synergistic vasorelaxation
C) Candesartan and amlodipine are additive rather than synergistic -- the fellow's premise is incorrect; antihypertensive drugs acting through different mechanisms always produce additive effects by definition, and true synergism can only occur between drugs acting at the same receptor through competitive interactions
D) The synergism is pharmacokinetic rather than pharmacodynamic -- amlodipine is a CYP3A4 substrate and candesartan inhibits CYP3A4, raising amlodipine plasma concentrations above what the prescribed dose alone would achieve; the enhanced antihypertensive effect reflects elevated amlodipine exposure, not a pharmacodynamic interaction
E) The synergism is explained by Bliss independence -- because candesartan and amlodipine act through completely independent mechanisms with no shared pathway, their combined probability of producing blood pressure reduction exceeds the product of their individual probabilities, producing synergism by the Bliss independence definition
ANSWER: A
Rationale:
The synergism between candesartan and amlodipine is a well-recognized pharmacodynamic interaction that illustrates how complementary mechanisms can produce greater-than-additive effects through mutual removal of counter-regulatory responses. When amlodipine produces vasodilation, the resulting fall in blood pressure activates baroreceptor-mediated reflexes that increase sympathetic outflow and stimulate renin release from the kidney. The renin-angiotensin-aldosterone system (RAAS) activation generates angiotensin II, which causes vasoconstriction through AT1 receptors and thus partially opposes amlodipine's antihypertensive effect. Candesartan blocks AT1 receptors, preventing this angiotensin II-mediated counter-regulation. Simultaneously, candesartan itself activates the same compensatory sympathetic mechanisms by lowering blood pressure, and its own antihypertensive effect is partially limited by reflex sympathetic activation of vascular smooth muscle calcium channels -- which amlodipine blocks. Each drug therefore removes a key component of the counter-regulatory response that limits the other drug's effectiveness, producing mutual potentiation and synergistic antihypertensive effect. This is a pharmacodynamic interaction at the system level rather than at a single receptor.
Option B: Option B is incorrect -- while both drugs do ultimately reduce intracellular calcium, the mechanism described conflates pathways; candesartan reduces IP3-mediated calcium release but this is not its primary antihypertensive pathway at clinical doses; the synergism is not explained by simultaneous calcium depletion from two routes.
Option C: Option C is incorrect -- synergism can and does occur between drugs with different mechanisms when those mechanisms interact through shared physiological counter-regulatory pathways, as in this case; the premise that different mechanisms always produce only additivity is incorrect.
Option D: Option D is incorrect -- candesartan does not inhibit CYP3A4 in a clinically significant way; the interaction is pharmacodynamic, not pharmacokinetic.
Option E: Option E is incorrect -- Bliss independence predicts additivity for drugs with truly independent mechanisms (combined probability = product of individual probabilities); the candesartan-amlodipine synergism arises from mechanistic interdependence through shared counter-regulatory pathways, not from Bliss independence.
4. A 66-year-old man with newly diagnosed HIV infection and tuberculosis requires treatment for both conditions simultaneously. His infectious disease team notes that starting rifampicin for tuberculosis will significantly complicate his antiretroviral therapy. Which of the following best describes the pharmacological basis for this interaction and its management implications?
A) Rifampicin is a pharmacodynamic antagonist at the HIV integrase enzyme -- it competitively inhibits the same active site targeted by integrase strand transfer inhibitors (INSTIs) such as dolutegravir, requiring dose escalation of the INSTI to overcome competitive inhibition
B) Rifampicin and antiretroviral drugs compete for binding to serum albumin -- rifampicin's high protein binding (approximately 80%) displaces antiretrovirals from albumin, raising free antiretroviral concentrations transiently but then accelerating their renal elimination, producing net reduction in antiretroviral exposure
C) The interaction is both pharmacokinetic and pharmacodynamic -- rifampicin reduces antiretroviral plasma concentrations through CYP3A4 induction and simultaneously reduces viral target engagement by upregulating HIV protease expression through a nuclear receptor mechanism, requiring both dose adjustment and switch to a protease inhibitor-sparing regimen
D) Rifampicin is a potent inducer of CYP3A4, P-glycoprotein, and multiple other drug-metabolizing enzymes and transporters; most antiretroviral drugs -- particularly protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) -- are CYP3A4 substrates; rifampicin co-administration reduces antiretroviral plasma concentrations by 75-90% for some agents, potentially falling below minimum inhibitory concentrations and risking therapeutic failure and emergence of drug-resistant HIV; management requires either avoiding rifampicin in favor of rifabutin (a weaker CYP3A4 inducer) or switching to an antiretroviral regimen less susceptible to CYP3A4 induction, such as high-dose dolutegravir or tenofovir-based nucleoside backbone agents
E) Rifampicin upregulates HIV reverse transcriptase through activation of viral gene transcription via the pregnane X receptor (PXR) -- increased reverse transcriptase expression accelerates viral replication and requires dose escalation of nucleoside reverse transcriptase inhibitors to maintain virological suppression
ANSWER: D
Rationale:
The rifampicin-antiretroviral interaction is one of the most clinically significant drug interactions in infectious disease practice, affecting the management of millions of patients co-infected with HIV and tuberculosis globally. Rifampicin is among the most potent inducers of drug-metabolizing enzymes and transporters known. It activates the pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of CYP3A4, CYP2C9, P-glycoprotein, and multiple other metabolic enzymes. Most antiretroviral drugs that achieve therapeutic plasma concentrations through CYP3A4-dependent metabolism are severely affected: rifampicin reduces protease inhibitor plasma concentrations by 75-90%, essentially eliminating therapeutic exposure. NNRTIs such as efavirenz and nevirapine are also significantly reduced, though efavirenz can be used with dose adjustment. The practical management approach in most guidelines is to use rifabutin in place of rifampicin when antiretrovirals cannot be changed -- rifabutin is also a rifamycin-class drug effective against Mycobacterium tuberculosis but is a much weaker CYP3A4 inducer. Alternatively, integrase inhibitors such as dolutegravir (at higher doses) or raltegravir can be used with rifampicin because they are less dependent on CYP3A4 for their pharmacokinetics. Tenofovir-based nucleoside/nucleotide backbone agents are largely unaffected because they are not CYP3A4 substrates.
Option A: Option A is incorrect -- rifampicin does not pharmacodynamically inhibit HIV integrase; it has no direct antiviral activity against HIV and its effect on antiretroviral therapy is entirely pharmacokinetic.
Option B: Option B is incorrect -- protein binding displacement is rarely a clinically significant mechanism of drug interaction; the displaced free drug rapidly re-equilibrates and is available for metabolism and distribution; this is not the mechanism of the rifampicin-antiretroviral interaction.
Option C: Option C is incorrect -- rifampicin does not upregulate HIV protease expression through a nuclear receptor mechanism; HIV replication is not enhanced by rifampicin through a direct pharmacodynamic mechanism; the interaction is pharmacokinetic only.
Option E: Option E is incorrect -- rifampicin does not upregulate HIV reverse transcriptase through PXR activation; the PXR-mediated induction affects human (host) metabolizing enzymes, not viral enzymes; this option confuses the mechanism of CYP3A4 induction with a fictitious viral enzyme induction.
ANSWER KEY: Q1=E Q2=C Q3=A Q4=D
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.